Lv1
10 积分 2023-06-27 加入
Insights Into Vepdegestrant (ARV‐471): The First‐in‐Class Estrogen Receptor Proteolysis‐Targeting Chimera Approaching Food and Drug Administration Approval for Breast Cancer
1个月前
已完结
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer
1个月前
已完结
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer
2个月前
已完结
IL-10 targets IRF transcription factors to suppress IFN and inflammatory response genes by epigenetic mechanisms
8个月前
已完结
Structure-based decoupling of the pro- and anti-inflammatory functions of interleukin-10
9个月前
已完结
The role of transcription factors in shaping regulatory T cell identity
10个月前
已完结
Colorectal cancer: a comprehensive review of carcinogenesis, diagnosis, and novel strategies for classified treatments
10个月前
已完结
The potential of B7-H6 as a therapeutic target in cancer immunotherapy
10个月前
已完结
CD8 cis-targeted IL-2 drives potent antiviral activity against hepatitis B virus
11个月前
已完结
Preclinical development of ZED8, an 89Zr immuno-PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy
1年前
已完结
皖公网安备34019202002308
